Reuven Agami

Group leader

+31 20 512 2079

Reuven Agami is heading the Division of Oncogenomics at the Netherlands Cancer Institute, and a full professor of molecular genetics at the University of Rotterdam. He is also a member of the Oncode Institute The Netherlands. Traditionally, his laboratory develops genetic tools and novel strategies to interrogate cancer. He was the first to establish a system that mediates stable suppression of gene expression through RNA interference (Brummelkamp et al., 2002 Science; and Brummelkamp et al., 2002 Cancer Cell), and used it for large-scale functional RNAi screens (Kolfschoten et al., 2005 Cell).

Next, he developed large-scale microRNA screens (Voorhoeve et al., 2006 Cell), genetic screens for key RNA-binding in microRNA biology and alternative polyadenylation of mRNAs (Kedde et al., 2007 Cell; and Jenal et al., 2012 Cell), genetic tools to measure amino acid shortages and linking transcription to mRNA translation via RNA modifications (Loayza-Puch et al., 2016 Nature; and Slobodin et al., 2017 Cell, respectively), and lastly functional genetic screens for regulatory DNA elements (Korkmaz et al., 2016 Nature Biotechnology). Altogether, these significant achievements constitute a proven strong track record of developing novel genetic tools for identifying key players linking gene regulation and disease.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.